Abcam is continuing to deliver impressive results with underlying revenues increasing 20%. However, the company needs to penetrate new markets to sustain the strong growth that its high rating demands. China is the key market with major growth potential, where antibody sales are expected to increase at c 20% pa over the next decade. It will become particularly important to Abcam as Western research budgets in key mature markets are tightening following the recession.

Unlock the rest of this Article in 15 seconds

or Unlock with your email